STAT News vs Aescap

STAT delivers fast, deep, and tough-minded journalism about health, medicine, life sciences and the fast-moving business of making medicines. We take you inside academic labs, biotech boardrooms, and political backrooms. We cast a critical eye on scientific discoveries, scrutinize corporate strategies, and chronicle roiling battles for talent, money, and market share. We examine controversies and puncture hype. Follow our reporting and reporters on the go; read exclusive stories or save them for later.

This is the only app from a biotech investment firm that gives you direct, curated access to the sector news and portfolio developments that shape our investment decisions. Every day, clinical data readouts, regulatory rulings by the FDA and EMA, licensing deals, and scientific breakthroughs move biotech markets. Most of that flow is buried in noise. This app surfaces what matters, selected and contextualized by the same team that manages the Aescap portfolios. You'll find sector-wide developments alongside updates on our portfolio companies, so you can follow the names behind our investment thesis as events unfold. From a Phase III readout that changes a company's trajectory to an M&A announcement that validates years of research, we bring the signal to your screen. No other biotech fund puts its sector lens in your hands this way. Whether you are an Aescap investor or a professional tracking biotech and life sciences, this app is built to keep you ahead of what's next.